The treatment was initiated 10 days after tumor challenge and consisted of a single injection (108 plaque-forming units (PFUs)/mouse) of OVV-CXCR4-A or control EGFP-expressing virus (OVV). The gene discussed is CXCR4; the disease is neoplasm.